Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Country
- 🇨🇳China
- Ownership
- Joint Venture, Subsidiary
- Established
- 1997-04-16
- Employees
- -
- Market Cap
- -
- Website
- http://www.cttq.com
Clinical Trial of TQB2618 Injection Combined With TQB2450 Injection in Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-12-09
- Last Posted Date
- 2022-12-09
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 127
- Registration Number
- NCT05645315
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳Fujian Cancer Hospital, Fuzhou, Fujian, China
🇨🇳Tongji Hospital,Tongji Medical College of HUST, Wuhan, Hubei, China
A Bioequivalence Study of Dasatinib Tablet
- Conditions
- Interventions
- First Posted Date
- 2022-12-07
- Last Posted Date
- 2022-12-08
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 56
- Registration Number
- NCT05640804
- Locations
- 🇨🇳
Affiliated Hospital of Changchun University of Traditional Chinese Medicine, Changchun, Jilin, China
A Study to Evaluate the Sensitivity and Specificity of Inhaled Methacholine in Bronchial Provocation Test
- First Posted Date
- 2022-12-02
- Last Posted Date
- 2022-12-02
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 280
- Registration Number
- NCT05634473
- Locations
- 🇨🇳
The First Hospital of Lanzhou University, Lanzhou, Gansu, China
🇨🇳Beijing Chaoyang Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳Zhejiang Provincial Hospital of Chinese Medicine, Hangzhou, Zhejiang, China
Tolerability and Pharmacokinetics Study of TQB3702 Tablets in Hematologic Tumor Subjects
- First Posted Date
- 2022-11-09
- Last Posted Date
- 2022-11-09
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 137
- Registration Number
- NCT05610202
- Locations
- 🇨🇳
The Cancer Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China
🇨🇳The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
To Evaluate the Efficacy and Safety of TQC3564 Tablets in the Treatment of Persistent Allergic Rhinitis
- Conditions
- Interventions
- First Posted Date
- 2022-11-07
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT05607446
- Locations
- 🇨🇳
Xiangya Hospital Central South University, Changsha, Hunan, China
TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
- First Posted Date
- 2022-10-03
- Last Posted Date
- 2022-12-01
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 90
- Registration Number
- NCT05563480
- Locations
- 🇨🇳
The Fifth Affiliated Hospital Sun Yat sen University, Zhuhai, Guangdong, China
🇨🇳Xiangya Hospital Central South University, Changsha, Hunan, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Pharmacokinetic Study of Anlotinib Hydrochloride Capsules in Healthy Subjects and Liver Dysfunction Patients
- Conditions
- Interventions
- First Posted Date
- 2022-09-29
- Last Posted Date
- 2022-09-29
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT05559242
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
🇨🇳The Second Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China
TQB3616 Capsules in the Treatment of Dedifferentiated Liposarcoma
- Conditions
- Interventions
- First Posted Date
- 2022-08-11
- Last Posted Date
- 2022-08-11
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 118
- Registration Number
- NCT05496569
- Locations
- 🇨🇳
Zhongshan Hospital Fudan University, Shanghai, Shanghai, China
🇨🇳Peking University First Hospital, Beijing, Beijing, China
🇨🇳Peking University People's Hospital, Beijing, Beijing, China
Clinical Study of Recombinant Human Activated Coagulation Factor VII for Injection in Patients With Hemophilia With Inhibitor
- Conditions
- Interventions
- First Posted Date
- 2022-08-04
- Last Posted Date
- 2022-08-04
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT05487976
- Locations
- 🇨🇳
The First Hospital of Lanzhou University, Lanzhou, Gansu, China
🇨🇳Henan Provincial People's Hospital, Zhengzhou, Henan, China
🇨🇳Xiangya Hospital Central South University, Changsha, Hunan, China
Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.
- Conditions
- Interventions
- First Posted Date
- 2022-08-01
- Last Posted Date
- 2023-07-24
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 79
- Registration Number
- NCT05481645
- Locations
- 🇨🇳
Yantai Yuhuangding Hospital, Yantai, Shandong, China
🇨🇳Hunan Cancer Hospital, Changsha, Hunan, China
🇨🇳Shandong Cancer Hospital, Jinan, Shandong, China